The global Plant-based biologics market is envisioned to garner $182.9 million by 2031, growing from $116.1 million in 2021 at a CAGR of 4.8% from 2022 to 2031.
The current production platforms, which are mostly based on mammalian cell culture, cannot meet the expanding global demand for human biologics due to exorbitant costs and restricted scalability. However, recent advances in plant expression vector generation, downstream processing, and glycoengineering have established plants as a preferable alternative for biologic production. Plant-based methods not only provide typical benefits such as appropriate eukaryotic protein modification, cheap cost, high scalability, and higher safety, but also enable for the rapid manufacture of biologics to control possible pandemics or with specialized glycoforms for improved efficacy or safety. The use of plant-based biologics has several advantages, including the ability to produce complex molecules at a lower cost than traditional systems, scalability to meet global demand, and improved safety due to the lack of potential human pathogens.
Environmental conditions, plant genetics, and post-harvest processing all have an impact on the quality of plant-based biologics. These factors can have an effect on the uniformity and purity of the end product, which is critical for the safety of biologics and efficacy. Ensuring consistent and high-quality production of plant-based biologics necessitates specialized knowledge and expertise, which may be absent in some instances. These factors are anticipated to hamper the growth of the plant-based biologics market growth.
The plant-based biologics market has expanded fast in recent years, driven by rise in biologics demand and the desire for more cost-effective and sustainable manufacturing methods. Duckweed plants are little water plants that grow quickly and are easy to cultivate. They are being researched as a potential platform for the manufacture of a wide range of biologics, including antibodies, enzymes, and vaccines. Duckweed plants have an advantage in biologics manufacturing because they can perform post-translational changes similar to mammalian cells, leading to proteins that closely resemble human proteins. Moreover, duckweed plants can generate biologics at a significantly lower cost than typical manufacturing platforms, making them a more cost-effective and scalable solution.
The pandemic of COVID-19 has had a substantial influence on many industries, including the plant-based biologics industry. The epidemic caused interruptions in the biologics supply chain, manufacturing, and distribution, which hampered growth of the industry. The pandemic has also caused delays in clinical trials and the approval process for novel biologics. Many companies were forced to suspend their research and development activities, resulting in a slowdown in the development of new products. Furthermore, the COVID-19 pandemic has caused significant disruptions to the global workforce, resulting in a reduced availability of skilled workers. The pandemic has forced many businesses to close temporarily or permanently, leading to job losses and decreased economic activity. In addition, many workers have been hesitant to return to work due to concerns about their health and safety. However, the pandemic has underlined the significance of creating more sustainable and cost-effective biologic production technologies. This has led to an increased interest in plant-based biologics, which have the potential to be produced at a lower cost and with faster turnaround times than traditional production methods.
The key players profiled in this report include Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., and Eleva GmbH
The current production platforms, which are mostly based on mammalian cell culture, cannot meet the expanding global demand for human biologics due to exorbitant costs and restricted scalability. However, recent advances in plant expression vector generation, downstream processing, and glycoengineering have established plants as a preferable alternative for biologic production. Plant-based methods not only provide typical benefits such as appropriate eukaryotic protein modification, cheap cost, high scalability, and higher safety, but also enable for the rapid manufacture of biologics to control possible pandemics or with specialized glycoforms for improved efficacy or safety. The use of plant-based biologics has several advantages, including the ability to produce complex molecules at a lower cost than traditional systems, scalability to meet global demand, and improved safety due to the lack of potential human pathogens.
Environmental conditions, plant genetics, and post-harvest processing all have an impact on the quality of plant-based biologics. These factors can have an effect on the uniformity and purity of the end product, which is critical for the safety of biologics and efficacy. Ensuring consistent and high-quality production of plant-based biologics necessitates specialized knowledge and expertise, which may be absent in some instances. These factors are anticipated to hamper the growth of the plant-based biologics market growth.
The plant-based biologics market has expanded fast in recent years, driven by rise in biologics demand and the desire for more cost-effective and sustainable manufacturing methods. Duckweed plants are little water plants that grow quickly and are easy to cultivate. They are being researched as a potential platform for the manufacture of a wide range of biologics, including antibodies, enzymes, and vaccines. Duckweed plants have an advantage in biologics manufacturing because they can perform post-translational changes similar to mammalian cells, leading to proteins that closely resemble human proteins. Moreover, duckweed plants can generate biologics at a significantly lower cost than typical manufacturing platforms, making them a more cost-effective and scalable solution.
The pandemic of COVID-19 has had a substantial influence on many industries, including the plant-based biologics industry. The epidemic caused interruptions in the biologics supply chain, manufacturing, and distribution, which hampered growth of the industry. The pandemic has also caused delays in clinical trials and the approval process for novel biologics. Many companies were forced to suspend their research and development activities, resulting in a slowdown in the development of new products. Furthermore, the COVID-19 pandemic has caused significant disruptions to the global workforce, resulting in a reduced availability of skilled workers. The pandemic has forced many businesses to close temporarily or permanently, leading to job losses and decreased economic activity. In addition, many workers have been hesitant to return to work due to concerns about their health and safety. However, the pandemic has underlined the significance of creating more sustainable and cost-effective biologic production technologies. This has led to an increased interest in plant-based biologics, which have the potential to be produced at a lower cost and with faster turnaround times than traditional production methods.
The key players profiled in this report include Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., and Eleva GmbH
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the plant-based biologics market analysis from 2021 to 2031 to identify the prevailing plant-based biologics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the plant-based biologics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global plant-based biologics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product Type
- Leaf-based
- Seed-Based
- Fruit-based
- Others
By Source
- Carrot
- Tobacco
- Rice
- Duckweed
- Others
By Target Disease
- Gaucher Disease
- Fabry Disease
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- UAE
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Leaf Expression Systems
- Zea Biosciences
- Planet Biotechnology Inc.
- InVitria
- plantform corporation
- IBIO, Inc.
- Mapp Biopharmaceutical, Inc.
- Ventria Bioscience Inc.
- Medicago Inc.
- Eleva GmbH
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: PLANT-BASED BIOLOGICS MARKET, BY PRODUCT TYPE
CHAPTER 5: PLANT-BASED BIOLOGICS MARKET, BY SOURCE
CHAPTER 6: PLANT-BASED BIOLOGICS MARKET, BY TARGET DISEASE
CHAPTER 7: PLANT-BASED BIOLOGICS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Leaf Expression Systems
- Zea Biosciences
- Planet Biotechnology Inc.
- InVitria
- plantform corporation
- IBIO, Inc.
- Mapp Biopharmaceutical, Inc.
- Ventria Bioscience Inc.
- Medicago Inc.
- Eleva GmbH
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
